GlassScriptPhysician profile
Darrin D Scherer
NPI 1346354396
$3,229.74
in general payments reported to CMS, 2019-2025
29 companies · $784 in 2025
The $784 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $140 · 2021: $14.61 · 2022: $391 · 2023: $727 · 2024: $608 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,119.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $745.23 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $449.74 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $430.98 | 2020-2025 | Mounjaro, Jardiance, Trulicity |
| Novo Nordisk INC | $372.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $198.96 | 2019-2025 | Proclaim, Freestyle Libre 2, Octrode |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.55 | 2019-2025 | Jardiance |
| Amgen INC. | $135.32 | 2019-2023 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $121.20 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $90.63 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $77.30 | 2023-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $44.28 | 2019-2020 | |
| Allergan, INC. | $36.14 | 2019 | |
| Amarin Pharma, INC. | $34.07 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $31.42 | 2022 | |
| Inspire Medical Systems, INC. | $31.20 | 2025 | Inspire |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $27.80 | 2023 | |
| Pfizer INC. | $27.22 | 2019-2024 | |
| Medtronic Vascular, INC. | $26.86 | 2019-2020 | |
| Boston Scientific Corporation | $26.55 | 2019 | |
| Nevro Corp. | $21.51 | 2022 | |
| Biotronik Nro, INC. | $21.23 | 2024 | Prospera |
| Corcept Therapeutics | $19.60 | 2022 | |
| W. L. Gore & Associates, INC. | $19.30 | 2023 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Merck Sharp & Dohme LLC | $18.62 | 2019 | |
| Medtronic USA, INC. | $18.19 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.33 | 2019 | |
| Tonix Medicines, INC. | $14.18 | 2025 | Tonmya |
| Horizon Therapeutics Plc | $11.79 | 2019 | |
| Shire North American Group INC | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darrin Scherer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.